



For immediate release

Seinäjoki, Finland 27.02.2023

Eevia Health Plc receives a 132 KSEK / 12 KEUR sales order for a chaga extract

Eevia Health Plc ("Eevia" or "The Company") has received a 12 KEUR sales order for Feno-Chaga® M from a health-food customer in Finland

The direct customer is a leading and fastest growing super-food company in Finland.

The sales value to Eevia of this new order is c. KEUR 12 EUR. The product is a chaga extract standardized for polysaccharides, especially beta glucans 1.3/1.6.

The order is expected to be followed by further repeat orders in the future.

For further information, please contact:

Stein Ulve, CEO, Eevia Health Plc

Email: stein.ulve@eeviahealth.com

Telephone: +358 400 22 5967



INFORMATION ABOUT EEVIA HEALTH PLC

Eevia Health Plc, founded in March 2017, addresses significant health problems with bioactive compounds extracted from plant materials. The materials are primarily wild harvested from the pristine Finnish and Swedish forests near or above the Arctic Circle. The extracts are sold B2B as ingredients in dietary supplements and food brands globally. These global brands utilize the ingredients in their consumer product formulas.

Eevia Health is a manufacturer of 100% organically certified plant extracts. Although a significant product, Elderberry extract, is made from cultivated berries, most of Eevia's other raw materials, such as bilberry, lingonberry, chaga-mushroom, and pine bark, are wild-harvested in a sustainable fashion.

Eevia Health operates a modern green-chemistry production facility in Finland. Manufacturing natural ingredients near the raw material harvest areas, Eevia offers a short value chain with an environmentally friendly carbon footprint, competitive pricing, and extreme transparency. Eevia listed its shares at Spotlight Stock Market in Sweden in June 2021, with the short name (ticker) [EEVIA](#).

To learn more, please visit www.eeviahealth.com or follow Eevia Health on LinkedIn@EeviaHealth.